JP2017502961A - グルコセレブロシダーゼモジュレーターおよびその使用 - Google Patents

グルコセレブロシダーゼモジュレーターおよびその使用 Download PDF

Info

Publication number
JP2017502961A
JP2017502961A JP2016543197A JP2016543197A JP2017502961A JP 2017502961 A JP2017502961 A JP 2017502961A JP 2016543197 A JP2016543197 A JP 2016543197A JP 2016543197 A JP2016543197 A JP 2016543197A JP 2017502961 A JP2017502961 A JP 2017502961A
Authority
JP
Japan
Prior art keywords
gcase
azaspiro
octane
diol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016543197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502961A5 (enExample
Inventor
ラメシュ カウル
ラメシュ カウル
アーネスト ジェイ マッキーチャン
アーネスト ジェイ マッキーチャン
ジャンユ スン
ジャンユ スン
デイヴィッド ジェイ ヴォカドロ
デイヴィッド ジェイ ヴォカドロ
ユアンシー ジョウ
ユアンシー ジョウ
ヨンバオ ジュー
ヨンバオ ジュー
Original Assignee
アレクトス セラピューティックス インコーポレイテッド
アレクトス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクトス セラピューティックス インコーポレイテッド, アレクトス セラピューティックス インコーポレイテッド filed Critical アレクトス セラピューティックス インコーポレイテッド
Publication of JP2017502961A publication Critical patent/JP2017502961A/ja
Publication of JP2017502961A5 publication Critical patent/JP2017502961A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2016543197A 2013-12-23 2014-12-22 グルコセレブロシダーゼモジュレーターおよびその使用 Pending JP2017502961A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361920160P 2013-12-23 2013-12-23
US61/920,160 2013-12-23
US201462005196P 2014-05-30 2014-05-30
US62/005,196 2014-05-30
PCT/CA2014/051252 WO2015095963A1 (en) 2013-12-23 2014-12-22 Glucocerebrosidase modulators and uses thereof

Publications (2)

Publication Number Publication Date
JP2017502961A true JP2017502961A (ja) 2017-01-26
JP2017502961A5 JP2017502961A5 (enExample) 2018-02-08

Family

ID=53477250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016543197A Pending JP2017502961A (ja) 2013-12-23 2014-12-22 グルコセレブロシダーゼモジュレーターおよびその使用

Country Status (4)

Country Link
US (2) US9796680B2 (enExample)
EP (1) EP3087056A4 (enExample)
JP (1) JP2017502961A (enExample)
WO (1) WO2015095963A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021501135A (ja) * 2017-10-26 2021-01-14 シャイア ヒューマン ジェネティック セラピーズ インコーポレイテッド グルコセレブロシダーゼ及びイソファゴミンを含む製剤
JP2022530017A (ja) * 2019-04-25 2022-06-27 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105631432B (zh) * 2016-01-04 2020-12-08 京东方科技集团股份有限公司 指纹探测电路及驱动方法和显示装置
CA3043709A1 (en) * 2016-11-14 2018-05-17 Berg Llc Methods for treating parkinson's disease
CN108530375B (zh) * 2018-05-29 2020-04-21 南京药石科技股份有限公司 4-氧杂-7-氮杂螺[2.5]辛烷或其盐的中间体及制备方法
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020223136A1 (en) * 2019-05-02 2020-11-05 Merck Sharp & Dohme Corp. Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
BR112023022567A2 (pt) * 2021-04-30 2024-02-06 Vanqua Bio Inc Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos
EP4329881A4 (en) * 2021-04-30 2025-06-11 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
PE20242105A1 (es) * 2021-10-13 2024-10-28 Vanqua Bio Inc Moduladores de micromoleculas de la actividad de la glucocerebrosidasa y usos de estos

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512253A (ja) * 2003-11-12 2007-05-17 アミカス セラピューティックス インコーポレイテッド ゴーシェ病を治療するための、ヒドロキシピペリジン誘導体
JP2008523145A (ja) * 2004-12-13 2008-07-03 イーライ リリー アンド カンパニー リポキシゲナーゼ阻害剤としてのスピロ誘導体
WO2012058193A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
JP2013508366A (ja) * 2009-10-19 2013-03-07 アミカス セラピューティックス インコーポレイテッド 中枢神経系の変性障害を予防および／または治療するための新規の組成物
WO2013075227A1 (en) * 2011-11-25 2013-05-30 The Hospital For Sick Children β-GLUCOCEREBROSIDASE CHAPERONES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2040548B1 (en) 2006-06-23 2012-05-02 Amicus Therapeutics, Inc. Method for the treatment of neurological disorders by enhancing the activity of beta -glucocerebrosidase
WO2010118282A1 (en) 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating degenerative disorders of the central nervous system
MX337933B (es) 2009-10-19 2016-03-29 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
MX354127B (es) 2012-03-27 2018-02-14 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512253A (ja) * 2003-11-12 2007-05-17 アミカス セラピューティックス インコーポレイテッド ゴーシェ病を治療するための、ヒドロキシピペリジン誘導体
JP2008523145A (ja) * 2004-12-13 2008-07-03 イーライ リリー アンド カンパニー リポキシゲナーゼ阻害剤としてのスピロ誘導体
JP2013508366A (ja) * 2009-10-19 2013-03-07 アミカス セラピューティックス インコーポレイテッド 中枢神経系の変性障害を予防および／または治療するための新規の組成物
WO2012058193A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
WO2013075227A1 (en) * 2011-11-25 2013-05-30 The Hospital For Sick Children β-GLUCOCEREBROSIDASE CHAPERONES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEARSON, M. S. M. ET AL.: "The spirocyclopropyl moiety as a methyl surrogate in the structure of L-fucosidase and L-rhamnosidas", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 17(23), JPN6018039896, 2009, pages 8020 - 8026, ISSN: 0003896053 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021501135A (ja) * 2017-10-26 2021-01-14 シャイア ヒューマン ジェネティック セラピーズ インコーポレイテッド グルコセレブロシダーゼ及びイソファゴミンを含む製剤
JP2022530017A (ja) * 2019-04-25 2022-06-27 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤
JP7642561B2 (ja) 2019-04-25 2025-03-10 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Also Published As

Publication number Publication date
WO2015095963A1 (en) 2015-07-02
US9796680B2 (en) 2017-10-24
EP3087056A1 (en) 2016-11-02
EP3087056A4 (en) 2017-07-19
US10081601B2 (en) 2018-09-25
US20180009761A1 (en) 2018-01-11
US20170029379A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
JP2017502961A (ja) グルコセレブロシダーゼモジュレーターおよびその使用
US11802122B2 (en) 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
ES2390937T3 (es) Espirociclos como inhibidores de 11-beta hidroxilesteroide deshidrogenasa tipo 1
JP2021105028A (ja) ヘテロ環式化合物およびそれらの使用
US20220380338A1 (en) Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
TWI629276B (zh) 咪唑并嗒化合物
US20240246932A1 (en) Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
EA032443B1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
RU2521286C2 (ru) Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани
RS56111B1 (sr) Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme
EP3828174A1 (en) Pyridazinone derivative
CN115803025B (zh) 非溶酶体葡糖神经酰胺酶抑制剂及其用途
JP7674389B2 (ja) 非リソソームグルコシルセラミダーゼ阻害剤及びその使用
JP7594548B2 (ja) 非リソソームグルコシルセラミダーゼ阻害剤及びその使用
TWI879947B (zh) 取代的氮雜五元環類化合物及其在藥物中的應用
US20250129080A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2025019454A2 (en) Substituted ergolines
WO2025137342A2 (en) 5-carboxamido and 5-carboxyalkyl phenethylamines
HK40053244A (en) Pyridazinone derivative
HK40011011A (en) Cannabinoid receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190516